← Leaderboards
Alex Y Strongin
Burnham Institute For Medical Research
$23,566,042
Attributed
$26,333,993
Total exposure
13
Grants
11
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.6M · FY2005–17$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
Funding mix
By agency
NIH$26,333,993 · 13
By mechanism
R01$12,457,160 · 4
U01$12,047,642 · 2
R21$1,526,980 · 3
U54$302,211 · 4
Top collaborators
- Veronica Shubayev6 shared
- Tony L Yaksh6 shared
- Sujan Shresta2 shared
- Alexey V Terskikh2 shared
Others in their field
Top investigators on “Proteolysis”
- Alexander J Varshavsky · California Institute Of Technology$23,104,416
- Eric S. Orwoll · Oregon Health And Science University$20,906,524
- John S Condeelis · Yeshiva University$19,952,591
- Michele Pagano · New York University School Of Medicine$18,357,000
- Stephen C. Blacklow · Massachusetts Institute Of Technology$16,591,203
- Chih-Lueh Albert Wang · Boston Biomedical Research Institute$16,375,297
Research focus
ProteolysisProgramsBaseCellsPathway InteractionsGenesSignal TransductionMatrix MetalloproteinasesTraffickingPeptide HydrolasesCell MotilityExtracellular MatrixReceptorLeadBiochemicalDesignMolecularMalignant NeoplasmsCell SurfaceTumorLinkCancer CellInhibitor/AntagonistTumorigenic
Grant awards (54)
Host-pathogen interactions in ZIKV infection leading to microcephaly$236,250
R21 · FY2017 · NS · contact PI
(PQ10) Do microbiota alter the epigenetic landscape in human genome$212,063
R21 · FY2017 · CA · contact PI
Proteolysis of Myelin as a Source of Neuropathic Pain$687,775
R01 · FY2016 · DE
Host-pathogen interactions in ZIKV infection leading to microcephaly$307,250
R21 · FY2016 · NS · contact PI
(PQ10) Do microbiota alter the epigenetic landscape in human genome$254,475
R21 · FY2016 · CA · contact PI
Proteolysis of Myelin as a Source of Neuropathic Pain$100,000
R01 · FY2016 · DE
Proteolysis of Myelin as a Source of Neuropathic Pain$693,414
R01 · FY2015 · DE
Biochemistry of MT1-MMP activation in malignancy$388,440
R01 · FY2015 · CA · contact PI
Proteolysis of Myelin as a Source of Neuropathic Pain$696,603
R01 · FY2014 · DE
Biochemistry of MT1-MMP activation in malignancy$376,787
R01 · FY2014 · CA · contact PI
Metalloproteinases in tumor neovascularization$317,497
R01 · FY2014 · CA · contact PI
Proteolysis of Myelin as a Source of Neuropathic Pain$670,052
R01 · FY2013 · DE
Biochemistry of MT1-MMP activation in malignancy$365,134
R01 · FY2013 · CA · contact PI
Metalloproteinases in tumor neovascularization$307,679
R01 · FY2013 · CA · contact PI
Proteolysis of Myelin as a Source of Neuropathic Pain$760,582
R01 · FY2012 · DE
Biochemistry of MT1-MMP activation in malignancy$380,472
R01 · FY2012 · CA · contact PI
Metalloproteinases in tumor neovascularization$320,603
R01 · FY2012 · CA · contact PI
Biochemistry of MT1-MMP activation in malignancy$380,472
R01 · FY2011 · CA · contact PI
Metalloproteinases in tumor neovascularization$320,603
R01 · FY2011 · CA · contact PI
Metalloproteinases in tumor neovascularization$146,897
R01 · FY2010 · CA · contact PI
Metalloproteinases in Tumor Neovascularization$285,237
R01 · FY2009 · CA · contact PI
MT1-MMP pericellular proteolysis in malignancy$47,697
R01 · FY2009 · CA · contact PI
Structure-based Drug Design for Smallpox Therapy$1,777,074
U01 · FY2008 · AI · contact PI
MT1-MMP pericellular proteolysis in malignancy$335,671
R01 · FY2008 · CA · contact PI
Metalloproteinases in Tumor Neovascularization$285,237
R01 · FY2008 · CA · contact PI
CORE 2 DB1: DEGRADOMICS OF THE CENTROSOME$77,130
U54 · FY2008 · RR · contact PI
Structure-based Drug Design for Smallpox Therapy$1,762,466
U01 · FY2007 · AI · contact PI
MT1-MMP pericellular proteolysis in malignancy$336,447
R01 · FY2007 · CA · contact PI
Metalloproteinases in Tumor Neovascularization$285,237
R01 · FY2007 · CA · contact PI
Hydroxamate-based therapy to target T cell homing in IDDM$278,192
R21 · FY2007 · DK · contact PI
CORE 2 DB1: DEGRADOMICS OF THE CENTROSOME$73,917
U54 · FY2007 · RR · contact PI
Structure-based Drug Design for Smallpox Therapy$1,766,082
U01 · FY2006 · AI · contact PI
Develop Effective Inhibitors of Anthrax Lethal Factor$920,383
U01 · FY2006 · AI · contact PI
MT1-MMP pericellular proteolysis in malignancy$347,295
R01 · FY2006 · CA · contact PI
Metalloproteinases in Tumor Neovascularization$293,756
R01 · FY2006 · CA · contact PI
Hydroxamate-based therapy to target T cell homing in IDDM$238,750
R21 · FY2006 · DK · contact PI
CORE 2 DB1: DEGRADOMICS OF THE CENTROSOME$79,676
U54 · FY2006 · RR · contact PI
Structure-based Drug Design for Smallpox Therapy$1,759,383
U01 · FY2005 · AI
Develop Effective Inhibitors of Anthrax Lethal Factor$915,082
U01 · FY2005 · AI
MT1-MMP pericellular proteolysis in malignancy$356,472
R01 · FY2005 · CA
Metalloproteinases in Tumor Neovascularization$300,825
R01 · FY2005 · CA
CORE 2 DB1: DEGRADOMICS OF THE CENTROSOME$71,488
U54 · FY2005 · RR
Structure-based Drug Design for Smallpox Therapy$1,708,117
U01 · FY2004 · AI
Develop Effective Inhibitors of Anthrax Lethal Factor$939,317
U01 · FY2004 · AI
MT1-MMP pericellular proteolysis in malignancy$380,041
R01 · FY2004 · CA
Develop Effective Inhibitors of Anthrax Lethal Factor$499,738
U01 · FY2003 · AI
CELL RECEPTORS DEFINE THE FATE OF MMP 2 IN CANCER$355,549
R01 · FY2003 · CA
METALLOPROTEINASES IN TUMOR NEOVASCULARIZATION$249,276
R01 · FY2003 · CA
CELL RECEPTORS DEFINE THE FATE OF MMP 2 IN CANCER$345,195
R01 · FY2002 · CA
METALLOPROTEINASES IN TUMOR NEOVASCULARIZATION$242,020
R01 · FY2002 · CA
CELL RECEPTORS DEFINE THE FATE OF MMP 2 IN CANCER$335,141
R01 · FY2001 · CA
METALLOPROTEINASES IN TUMOR NEOVASCULARIZATION$234,971
R01 · FY2001 · CA
CELL RECEPTORS DEFINE THE FATE OF MMP 2 IN CANCER$309,960
R01 · FY2000 · CA
METALLOPROTEINASES IN TUMOR NEOVASCULARIZATION$218,123
R01 · FY2000 · CA